HUTCHMED
Surfing the ‘waves’ towards profitabilityHUTCHMED
Delivering on sharpened goals and prioritiesHUTCHMED
ASCO 2023: a growing body of evidence for fruquintinibHUTCHMED
Significant 2022 achievements catalyse a promising 2023HUTCHMED
Delivering commercially and strategically during FY22HUTCHMED
Takeda licenses fruquintinib in $1.13bn ex-China dealHUTCHMED
First steps towards fruquintinib availability in the USHUTCHMED
A sharper focus on the path to profitabilityHUTCHMED
Fruquintinib should continue to bear fruitHUTCHMED
FRESCO-2 data support broad uptake in later-line mCRC